focus -WSS

focus

author：entertainment 2025-09-30 23:33:30 - browse：431

Photo illustration of Covid 19 testing swabs on a blue background. — Timothy Stenzel led the FDA's diagnostics division during the Covid-19 pandemic, as the agency scrambled to push through and validate accurate Covid tests. Adobe

Timothy Stenzel, the federal regulator who led the Food and Drug Administration’s diagnostics division during the chaotic time of Covid-19 pandemic, has left the agency. The FDA confirmed Thursday that Stenzel, who led the FDA’s office of in vitro diagnostics, retired at the end of 2023.

During the early days of the pandemic, Stenzel was in the middle of a turf battle between the Centers for Disease Control and Prevention and the FDA over the regulation of Covid tests. At one point, the CDC made Stenzel wait at its facility overnight after he arrived for a meeting on Covid test development, Politico reported at the time.

It was a hectic time. Testmakers rapidly introduced new Covid-19 screening products with little data, as it was a brand new virus. The pandemic especially laid bare FDA’s inability to control lab-developed tests (LDTs). Many of the Covid-19 PCR tests fell in this category. Early on, using powers granted by the public health emergency, the FDA required labs to apply for emergency use authorization. But a STAT investigation found that the Department of Health and Human Services told the FDA to stop this measure, despite knowing that many of the tests may have been inaccurate.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

entertainment

WSS

NIH study of ME/CFS points to clear biological hallmarks

Obesity drugs seen as possible treatment for liver disease MASH

R1 RCM gets $5.8 billion buyout offer from private equity firm

Why police arrested suspected Gilgo Beach killer away from his house

Obesity drugs seen as possible treatment for liver disease MASH

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

leisure time

focus

entertainment

Peter Hotez and the public health issue of online harassment

STAT readers on older presidents, polypills, Medicare, and more

DIEP, the 'gold standard' of breast reconstruction, is under threat

Europe sees delivery challenges ahead on Alzheimer's therapies

New air purifier tech could be key to improving indoor air quality

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

After affirmative action ruling, medical educators look to 'holistic review'

The Harvard botanist who searched for psychedelics in the Amazon

Wikipedia

Grail faces three suits alleging harassment, retaliation

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Ed Silverman on new gene therapies, biosimilars, coffee, and more

With competition flaring, obesity drug hits goal in liver disease study

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

Celiac disease study examines precisely how gluten triggers injury

entertainment

hotspot

explore

Wikipedia